Breaking News - The Fly

Open Search

PSTX

Poseida Therapeutics

$

()

Poseida Therapeutics management to meet with Piper Sandler

PSTX

4/24/2024 - 04:55am

Poseida Therapeutics management to meet with Piper Sandler

PSTX

4/16/2024 - 15:05pm

Poseida Therapeutics files to sell 8.33M shares of common stock for holders

PSTX

4/8/2024 - 17:04pm

Poseida: Phase 1 data supports potential of P-BCMA-ALLO1 therapy in MM

PSTX

4/8/2024 - 12:06pm

Poseida Therapeutics names Syed Rizvi, M.D., as Chief Medical Officer

PSTX

3/25/2024 - 16:06pm

Poseida Therapeutics granted FDA orphan designation for P-BCMA-ALLO1

PSTX , RHHBY

3/13/2024 - 16:07pm

Poseida Therapeutics' treatment of multiple myeloma gets FDA orphan designation

PSTX

3/12/2024 - 18:58pm

Poseida Therapeutics reports Q4 EPS (27c), consensus (39c)

PSTX

3/7/2024 - 16:12pm

Poseida Therapeutics price target raised to $10 from $8 at Piper Sandler

PSTX , RHHBY

12/11/2023 - 08:36am

Poseida Therapeutics price target raised by $5 at H.C. Wainwright, here's why

PSTX

12/11/2023 - 06:21am

Poseida presents efficacy, safety results from Phase 1 study of P-BCMA-ALLO1

PSTX , RHHBY

12/10/2023 - 16:53pm

Poseida Therapeutics reports Q3 EPS (35c), consensus (29c)

PSTX

11/9/2023 - 16:25pm

Poseida Therapeutics names Kristin Yarema, Ph.D as CEO, effective Jan 1, 2024

PSTX , ATRA

10/9/2023 - 16:32pm

Poseida Therapeutics price target lowered to $14 from $17 at Cantor Fitzgerald

PSTX

8/9/2023 - 07:28am

Poseida Therapeutics reports Q2 EPS (32c), consensus (53c)

PSTX

8/8/2023 - 16:29pm